Damora Therapeutics (DMRA) Capital Expenditures (2021 - 2025)
Damora Therapeutics' (DMRA) quarterly Capital Expenditures came in at -$837000.0 in Q4 2025, up 56.94% YoY from -$533309.7 in Q4 2024, and down 383.73% on a QoQ basis from $295000.0 in Q3 2025.
Damora Therapeutics (DMRA) Capital Expenditures (2021 - 2025) Analysis & Trends
Damora Therapeutics (DMRA) has 5 years of Capital Expenditures data on file, last reported at -$837000.0 in Q4 2025.
- Quarterly Capital Expenditures rose 56.94% year-over-year to -$837000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$166000.0 (up 82.89% YoY) and the FY2025 annual result came in at -$166000.0, up 82.89% from the prior year.
- Capital Expenditures eased to -$837000.0 in Q4 2025, from $295000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $776000.0 in Q2 2021 to a low of -$1.9 million in Q4 2024.
- A 5-year average of -$90200.0 and a median of $83500.0 in 2021 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2023 — Capital Expenditures plunged 1363.73% — and 2024, when it surged 3155.56%.
- Tracing DMRA's Capital Expenditures over 5 years: stood at $20000.0 in 2021, then jumped by 410.0% to $102000.0 in 2022, then sank by 1363.73% to -$1.3 million in 2023, then tumbled by 50.81% to -$1.9 million in 2024, then surged by 56.94% to -$837000.0 in 2025.
- The last three Capital Expenditures figures came in at -$837000.0 (Q4 2025), $295000.0 (Q3 2025), and $225000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.29 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.02 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 572,662.23 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 251.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 34.68 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.26 Mn |
| 10 | Damora Therapeutics | 1.92 Bn | 1.38 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -837,000.00 |
| Dec 31, 2025 | -837,000.00 |
| Sep 30, 2025 | 295,000.00 |
| Sep 30, 2025 | 295,000.00 |
| Jun 30, 2025 | 225,000.00 |
| Jun 30, 2025 | 225,000.00 |
| Mar 31, 2025 | 151,000.00 |
| Mar 31, 2025 | 151,000.00 |
| Dec 31, 2024 | -1.94 Mn |
| Dec 31, 2024 | -1.94 Mn |
| Sep 30, 2024 | 117,000.00 |
| Sep 30, 2024 | 117,000.00 |
| Jun 30, 2024 | 275,000.00 |
| Jun 30, 2024 | 275,000.00 |
| Mar 31, 2024 | 582,000.00 |
| Mar 31, 2024 | 582,000.00 |
| Dec 31, 2023 | -1.29 Mn |
| Dec 31, 2023 | -1.29 Mn |
| Sep 30, 2023 | -62,000.00 |
| Sep 30, 2023 | -62,000.00 |